A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept.
10.4078/jrd.2016.23.3.187
- Author:
Ji Hyoun KANG
1
;
Joon Ho AHN
;
Ji Eun YU
;
Ji Eun KIM
;
Yi Rang YIM
;
Jeong Won LEE
;
Kyung Eun LEE
;
Dong Jin PARK
;
Lihui WEN
;
Yong Wook PARK
;
Shin Seok LEE
Author Information
1. Division of Rheumatology, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea. shinseok@chonnam.ac.kr
- Publication Type:Case Report
- Keywords:
Etanercept;
Sarcoidosis;
Ankylosing spondylitis
- MeSH:
Adult;
Biopsy;
Chills;
Cough;
Diagnosis, Differential;
Etanercept*;
Humans;
Inflammation;
Lymph Nodes;
Lymphatic Diseases;
Myalgia;
Necrosis;
Sarcoidosis*;
Spondylitis, Ankylosing;
Thorax;
Tumor Necrosis Factor-alpha;
Weight Loss
- From:Journal of Rheumatic Diseases
2016;23(3):187-192
- CountryRepublic of Korea
- Language:English
-
Abstract:
A 31-year-old man who had been prescribed etanercept over a 3-year period for treatment of ankylosing spondylitis presented with newly developed dry cough, chills, myalgia, and weight loss. Chest computed tomography showed multiple reticulonodular pulmonary infiltrates and bilateral mediastinal, hilar, and peribronchial lymphadenopathy. Biopsy of a paratracheal lymph node revealed chronic granulomatous inflammation without necrosis, and the serum angiotensin-converting enzyme level was elevated. Sarcoidosis was diagnosed. His laboratory and radiological findings, and clinical symptoms improved only after discontinuation of etanercept without treatment. Although etanercept-induced sarcoidosis is rare, this case report suggests that sarcoidosis should be considered in the differential diagnosis of patients treated with the tumor necrosis factor inhibitor.
